You are here

Products

Yeda, the technology transfer arm of the Weizmann Institute of Science, has signed a license agreement with ’3i.’ Other microscopy systems based on Weizmann research are being sold by ‘Idea Bio-Medical’ The imaging potential of cutting-edge microscopes will soon be expanded thanks to Weizmann Institute inventions. A licensing agreement for developing these inventions into commercial products has been signed recently...Read more >
STEBA Biotech is a privately owned biotechnology company headquartered in Luxembourg with offices in France, Israel, Switzerland, and the US. Steba Biotech’s flagship product, TOOKAD®, for treatment of prostate cancer, is a first-in-class photosensitizer derived from palladium-substituted bacteriochlorophyll and developed in collaboration with the Weizmann Institute. It was designed to address limitations of...Read more >
ImmunArray, developer of the iCHIP™, a groundbreaking in-vitro auto-antibody profiling platform is pleased to announce the launch of their first commercial diagnostic product, SLE-key™ Rule Out, designed to provide physicians the ability to rule out a diagnosis of SLE (Systemic Lupus Erythematous) with a high degree of certainty. The test was developed and validated on a panel of 200 antigens in a 500 patient...Read more >
Hermes system WiScan® Hermes is a High content screening Fluorescence and Bright Field scanning system which operates at extremely high speeds of image acquisition, and generates exceptionally high quality images. Hermes covers a range of 7 wavelength channels and transmitted light. It accommodates magnification up to 60X, and various sized multi-well plates, slides, dish, and microarrays. Hermes is modular,...Read more >
Vitamin Alpha D3 is a molecule discovered by Institute researchers and produced under license by Teva Pharmaceuticals Ltd. for the treatment of osteoporosis and bone decalcification.Read more >
Centre Hospitalier Universitaire (CHU) d'Angers in France is conducting a clinical trial of RP103 called "CYST-HD Multicentre study of treatment of Huntington’s Disease with cysteamine, a randomized, controlled, double-blind multicenter phase II-III trial vs placebo." The trial, in collaboration with Raptor, commenced in October 2010. Clinical researchers at CHU d’Angers, with input from researchers at the Curie...Read more >
(Recombinant interferon beta), identical to the native molecule and registered for the treatment of multiple sclerosis and several viral diseases, licensed to Inter-Lab Ltd., a Serono company. Indicated for Multiple Sclerosis Rebif is a recombinant interferon beta 1a. Rebif is marketed worldwide by Merck Serono. 1982: Licensed to Interpharm. 2007 Sales: Euro 1.2 Billion 2007 Market share: 32%Read more >
NanoLubTM, is the world’s first commercial solid lubricant based on spherical inorganic nanoparticles. NanoLubTM reduces friction & wear significantly better than conventional lubricants. Licensed to Nanomaterials Inc. The company has been selected for the prestigious Red Herring Top 100 INNOVATORS Award for 2004. NanoLubTM is the world's first commercial solid lubricant based on spherical inorganic...Read more >
Improved crop varieties and hybrid cultivars of cucumbers and melons are under license to Israeli seed companies.Read more >
GeneCards® is a searchable, integrated database of human genes that provides concise genomic related information, on all known and predicted human genes The GeneCards human gene database extracts and integrates a carefully selected subset of gene related transcriptomic, genetic, proteomic, functional and disease information, from dozens of relevant sources. It provides robust user-friendly access to up-to-date...Read more >
Kibbutz Dorot is the largest producer of garlic in Israel. Following research conducted at the Weizmann Institute of Science, Kibbutz Dorot has developed a garlic capsule – a revolutionary food supplement in which the amount of allicin produced and preserved in the garlic is carefully controlled, thus granting consumers the maximum benefit from the medical properties of this substance. As opposed to whole garlic,...Read more >
Native interferon beta), licensed to Inter-Lab Ltd., a Serono company, and used as an antiviral and anti-cancer drug, with sales exceeding 40$ million annually, until replaced by Rebif®.Read more >
An antibody based therapy presenting synergism with conventional chemotherapy. The synergistic effect was invented at the Weizmann Institute. Erbitux was developed by ImClone Systems and approved by the FDA in 2001.Imclone has a license to the synergism patent. Erbitux Sales in 2007 exceeded 1B$. Erbitux is an antibody based therapy presenting synergism with conventional chemotherapy. The synergistic effect was...Read more >
A recombinant hepatitis B vaccine that integrates the S, pre-S1, and pre-S2 surface proteins of the hepatitis B virus. Enables successful immunization with significantly lower doses of vaccine than other recombinant hepatitis B vaccines. Licensed to Bio-Technology General, Inc., a subsidiary of Ferring Inc. Bio-Hep-B is marketed in Israel and registrations in other countries are under way.Read more >
This algorithm is licensed to NDS Ltd., and is widely used as the basis for television set-top box smart cards. To date, over 50 million smart cards are in use throughout the world. Technology developed by Mathematics department at the Weizmann Institute of Science. Licensed in the early 90’s to a start up company in Jerusalem, later purchased by NDS group. 52 million TV set-top box smart-cards in use worldwide...Read more >
Copaxone - as marketed by Teva Pharmaceuticals
The first innovative drug to be developed in Israel and to receive FDA approval, Copaxone® is a unique multiple sclerosis immunomodulator: the first and only non-interferon agent for the treatment of relapsing-remitting multiple sclerosis. Copaxone® is licensed to Teva Pharmaceuticals Ltd. Indicated for Multiple Sclerosis COPAXONE represents a new class of drugs for the treatment of the disease. Copaxone is a...Read more >
(Beta-carotene), a health food product with possible anti-cancer properties, extracted from Dunaliella, a local alga, licensed to Nikken Sohonsha Corporation . A Beta-carotene- based health food product, with possible anti-cancer properties, derived by an Institute-developed process from Dunaliella algae. Produced in Eilat (on the Red Sea) and exported as a food supplement to Japan. Marketed successfully in Japan by...Read more >